The new document answers questions regarding implementation of the ICH Q7 guidance on GMPs for APIs.
On April 19, 2018, FDA published a guidance document that answers questions about the implementation of the International Council for Harmonization (ICH) Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. ICH Q7 helps pharmaceutical companies ensure that APIs meet quality and purity characteristics. This Q&A document is in response to industry requests for clarification of some ICH Q7 sections.
Topics addressed in the Q&A document include quality management, personnel training, facilities, process equipment, documentation, materials management, production, storage, and validation. Specifically, the document clarifies requirements for releasing raw materials, sampling, product quality review, risk management, acceptance criteria, evaluation of material suppliers, and more.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.